Cost of treating mental illness from a managed care perspective. Discussion.
Symposium "Pharmacoeconomic Factors Related to the Treatment of Schizophrenia". Chicago, IL, USA, 1998/04/08.
The issue of cost-effectiveness in the pharmacoeconomics of mental illness is a new concept.
As methodologies for exploring this subject unfold, the most fundamental objective for health care professionals and managed care officials is to find ways in which currently available resources can be used most effectively.
The managed care perspective is highly cost-based within the market serves.
In addition to cost, other factors that influence the managed care perspective are a short-term focus, segmentation of budgets, and measurable indicators of outcome, cost, and quality of care.
The cost of new psychopharmacology-especially antidepressants and antipsychotics-may be many times that of traditional drugs, and concern about increased drug costs is present in many managed care organizations.
Several issues must be addressed to prevent restriction of pharmacotherapeutics in managed care settings.
For example, a focus on both outcomes and practice guidelines is needed to help allocate limited resources fairly.
This article suggests ways in which available resources can be used more effectively to treat mental illness within the present health care system.
Mots-clés Pascal : Trouble psychiatrique, Chimiothérapie, Traitement, Psychotrope, Analyse coût, Système santé, Soin intégré, Santé mentale, Homme
Mots-clés Pascal anglais : Mental disorder, Chemotherapy, Treatment, Psychotropic, Cost analysis, Health system, Managed care, Mental health, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0190277
Code Inist : 002B02B11. Création : 16/11/1999.